Vicplas Intl 569

SGD 0.062 +0.00% +0.00 Updated 19 Nov 2026, 13:16 SGT

Company profile

The business, the people and the ownership behind Vicplas Intl.

Business overview

About the company

Vicplas International’s businesses include medical device contract manufacturing through Forefront. Its shareholder disclosures describe close integration between Forefront and customers’ product teams in developing and producing medical devices.

Shareholder questions and answers ↗ Reviewed 2026-10-23 · Source dated 2025-11-26. PDF p. 1

Listed security

Company & listing

Full Company Name
VICPLAS INTERNATIONAL LTD
Trading Currency
SGD
Website
www.vicplas.com
Listing
Listed on 22 April 1999 on SGX Sesdaq 12 January 2009 on SGX Mainboard
ISIN Code
SG1G57870584

Board & management

Leadership

Four non-executive board members and four senior executives are disclosed. Walter Tarca is Group CEO and does not sit on the Board; Gan Ying Hui is CFO. Cheng Liang ceased as Group CEO in July2022 and remains Managing Director of the pipes and pipe fittings segment. Cheng Hsheng also became Deputy Managing Director of that segment in October2024.

Toon Chin Liang appears in FY2025 remuneration disclosures but resigned15August2025; he is not presented as current management.

Yeo Wico

Non-executive Chairman

Board of Directors

Jane Rose Philomene Gaines-Cooper

Non-executive Director

Board of Directors

Ng Beng Tiong

Non-executive Lead Independent Director

Board of Directors

Yeo Kah Chong Mark Andrew

Non-executive Independent Director

Board of Directors

Walter Tarca

Group Chief Executive Officer

Group; not a director

Gan Ying Hui

Chief Financial Officer

Group

Cheng Hsheng

Group Operations Director

Group

Cheng Liang

Managing Director

Pipes and pipe fittings segment of the Group

Roles listed in Annual Report 2025; current appointments are not independently verified.

Holdings

Ownership

Share register as at13October2025:511,076,699 voting shares excluding461,000 treasury shares. Top20 holders total413,593,553 shares and80.93%; public holdings32.97%. Registered, beneficial and deemed holdings overlap and are not added.

Three registered percentages differ from rounding against the printed voting share count: Cheng Liang2.74% versus2.75%, DBS Nominees1.12% versus1.11%, Maybank Securities0.52% versus0.51%. Original percentages are retained.

Bird Island Trust terminated28February2025. Jane Rose Philomene Gaines-Cooper has absolute rights to the trust assets while legal title is being transferred; the trustee holds title as nominee pending transfer. CTX's own-account deemed255,168,861 shares arise from charges of280,852,441 shares less25,683,580 released. The separate printed disclosures are preserved.

Venner Capital S.A.

280,852,441 shares beneficially held; no deemed interest; total 280,852,441 shares; 54.95%.

Substantial shareholder; beneficial holding

CTX Treuhand AG, as trustee of the Bird Island Trust

No shares beneficially held; deemed interest of 280,852,441 shares; total 280,852,441 shares; 54.95%.

Substantial shareholder; deemed interest as trustee of Bird Island Trust

CTX Treuhand AG

No shares beneficially held; deemed interest of 255,168,861 shares; total 255,168,861 shares; 49.93%.

Substantial shareholder; deemed interest for its own account following share charges

Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.

Registered & depository holders 20 holders

Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2025-10-13 · PDF p. 145

Registered holderInterestShares / unitsSource
Venner Capital S.A.280,852,441 shares; 54.95%.PDF p. 1452025-10-13
Jane Rose Philomene Gaines-Cooper23,854,200 shares; 4.67%.PDF p. 1452025-10-13
Cheng Liang14,029,497 shares; 2.74%.PDF p. 1452025-10-13
Raffles Nominees (Pte) Limited13,759,587 shares; 2.69%.PDF p. 1452025-10-13
Phillip Securities Pte Ltd11,069,494 shares; 2.17%.PDF p. 1452025-10-13
UOB Kay Hian Pte Ltd10,239,404 shares; 2.00%.PDF p. 1452025-10-13
Lim Sim Moi9,938,000 shares; 1.94%.PDF p. 1452025-10-13
Ho Lai Heng6,089,000 shares; 1.19%.PDF p. 1452025-10-13
DBS Nominees Pte Ltd5,691,702 shares; 1.12%.PDF p. 1452025-10-13
David Dangar Henry Honywood Curtis-Bennett5,100,000 shares; 1.00%.PDF p. 1452025-10-13
OCBC Securities Private Ltd4,810,466 shares; 0.94%.PDF p. 1452025-10-13
Loh Beng Seng4,402,318 shares; 0.86%.PDF p. 1452025-10-13
CGS International Securities Singapore Pte Ltd3,457,100 shares; 0.68%.PDF p. 1452025-10-13
Chua Kim Hua3,389,200 shares; 0.66%.PDF p. 1452025-10-13
Ng Cher Yan3,217,390 shares; 0.63%.PDF p. 1452025-10-13
IFast Financial Pte Ltd3,029,000 shares; 0.59%.PDF p. 1452025-10-13
Christopher Paul Lee3,000,000 shares; 0.59%.PDF p. 1452025-10-13
Lim Boon Hock2,700,585 shares; 0.53%.PDF p. 1452025-10-13
Maybank Securities Pte. Ltd.2,630,569 shares; 0.52%.PDF p. 1452025-10-13
Goh Han Peng (Wu Hanping)2,333,600 shares; 0.46%.PDF p. 1452025-10-13

Group structure

Subsidiaries and joint ventures

Twelve subsidiaries and the49%Cambodia joint venture are disclosed. Subsidiary table reports ownership interest and voting power at the named holding-parent level. No NCI at year end. All principal activities/countries and explicit subsidiary holding paths retained.

CompanyMarketOwnership interest
Vicplas Holdings Pte. Ltd.Company; 2025 and 2024PDF p. 124 Singapore; Manufacturing, trading and distributing of pipes and pipe fittings; FY2025 100%; FY2024 100%
Rimplas Industries Sdn. Bhd.Company; 2025 and 2024PDF p. 124 Malaysia; Manufacturing and distributing of pipes and pipe fittings; FY2025 100%; FY2024 100%
Forefront Medical Technology (Pte) LtdCompany; 2025 and 2024PDF p. 124 Singapore; Developing and manufacturing of medical devices; FY2025 100%; FY2024 100%
Forefront Medical Investment Pte. Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 Singapore; Developing and manufacturing of medical devices; FY2025 100%; FY2024 100%
Forefront Investment Pte. Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 Singapore; Investment holding; FY2025 100%; FY2024 100%
XentiQ (Pte.) Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 Singapore; Project design and engineering services; FY2025 100%; FY2024 100%
Forefront Medical Americas Pte. Ltd.Subsidiary of Forefront Medical Technology (Pte) Ltd; 2025 and 2024PDF p. 124 Singapore; Manufacture of medical and dental tools, instruments and supplies; FY2025 100%; FY2024 100%
Forefront (Xiamen) Medical Devices Co., LtdSubsidiary of Forefront Investment Pte. Ltd.; 2025 and 2024PDF p. 124 People’s Republic of China; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100%
Forefront Medical Technology (Jiangsu) Co., LtdSubsidiary of Forefront Medical Investment Pte. Ltd.; 2025 and 2024PDF p. 125 People’s Republic of China; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100%
Arrow Medical LimitedSubsidiary of Forefront Medical Investment Pte. Ltd.; 2025 and 2024PDF p. 125 United Kingdom; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100%
Arrow Medical Products LimitedSubsidiary of Arrow Medical Limited; 2025 and 2024PDF p. 125 United Kingdom; Manufacturing and assembly of medical devices; FY2025 100%; FY2024 100%
Vicplas Investment Pte. Ltd.Subsidiary of Vicplas Holdings Pte Ltd; 2025 and 2024PDF p. 125 Singapore; Investment holding; FY2025 100%; FY2024 100%
V&H Investment Co., LtdGroup joint venture; ownership interest and voting rights held by the Group; 2025 and 2024PDF p. 126 Cambodia; Buying, selling and operating of self-owned or leased real estate; FY2025 49%; FY2024 49%

Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.

Senior executives

Key management

Key management

ItemValuePeriod / scopeSource
Cheng Hsheng Group Operations Director; Deputy Managing Director of the pipes and pipe fittings segment Senior Management PDF p. 11
Gan Ying Hui Chief Financial Officer Senior Management PDF p. 11
Nor Hafiza Alwi Company Secretary Corporate information / Notice of AGM PDF p. 151

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Shareholding statistics

Share capital & shareholders

Share capital

ItemValuePeriod / scopeSource
Issued and Fully Paid-Up Capital (including Treasury Shares) $51,034,884 Company, as at October 13, 2025 · As at 2025-10-13 PDF p. 145
Issued and Fully Paid-Up Capital (excluding Treasury Shares) $50,997,284 Company, as at October 13, 2025 · As at 2025-10-13 PDF p. 145
Number of Issued Shares (excluding Treasury Shares) 511,076,699 shares Company, as at October 13, 2025 · As at 2025-10-13 PDF p. 145
Class of Shares Ordinary Shares Company · As at 2025-10-13 PDF p. 145
Voting Rights (excluding Treasury Shares) One Vote Per Share Company PDF p. 145

Treasury shares

ItemValuePeriod / scopeSource
Number/Percentage of Treasury Shares and Subsidiary Holdings 461,000 (0.09%) Company, as at October 13, 2025 · As at 2025-10-13 PDF p. 145
Treasury shares the Company paid $37,000 to acquire 461,000 of its own shares through market purchase Group and Company, July 31, 2025 PDF p. 134

Shareholding distribution

ItemValuePeriod / scopeSource
1 - 99 40 holders; 1.71%; 2,194 shares; 0.00% Distribution as at October 13, 2025; size of shareholdings 1-99 · As at 2025-10-13 PDF p. 145
100 - 1,000 233 holders; 9.96%; 195,201 shares; 0.04% Distribution as at October 13, 2025; size 100-1,000 · As at 2025-10-13 PDF p. 145
1,001 - 10,000 930 holders; 39.76%; 5,754,695 shares; 1.13% Distribution as at October 13, 2025; size 1,001-10,000 · As at 2025-10-13 PDF p. 145
10,001 - 1,000,000 1,106 holders; 47.29%; 76,517,676 shares; 14.97% Distribution as at October 13, 2025; size 10,001-1,000,000 · As at 2025-10-13 PDF p. 145
1,000,001 and above 30 holders; 1.28%; 428,606,933 shares; 83.86% Distribution as at October 13, 2025; size 1,000,001 and above · As at 2025-10-13 PDF p. 145
Total 2,339 holders; 100.00%; 511,076,699 shares; 100.00% Distribution as at October 13, 2025; total · As at 2025-10-13 PDF p. 145

Free float

ItemValuePeriod / scopeSource
Shares held by the public approximately 32.97% of the issued ordinary shares of the Company is held by the public Company, as at October 13, 2025 · As at 2025-10-13 PDF p. 145

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Related parties, people & properties

Other disclosures

Related party transactions

ItemValuePeriod / scopeSource
Venner Capital S.A. and subsidiaries and related parties 1,086 S$'000 Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S$100,000), FY2025 PDF p. 55
Legal fees expense (73) $'000 Group, 2025; entity in which a director is a partner (2024: (50)) PDF p. 113
Sale of goods 1,086 $'000 Group, 2025; group companies of the ultimate holding company (2024: 802) PDF p. 113
Compensation of directors and key management personnel 2,550 $'000 Group, 2025 (2024: 2,581) PDF p. 113

Contingent liabilities

ItemValuePeriod / scopeSource
Guarantee given to banks and financial institutions for credit facilities granted to subsidiaries (unsecured) 32,406 $'000 Company, 2025 (2024: 29,727) PDF p. 143

Director remuneration

ItemValuePeriod / scopeSource
Directors of the Company 281 $'000 Group, 2025 (2024: 285) PDF p. 139
FY2025 directors' fees S$280,651 FY2025 aggregate, subject to shareholder approval at AGM on November 28, 2025 PDF p. 47
Walter Tarca 751,015 S$ Group Chief Executive Officer (not a director), FY2025 PDF p. 48

Employees

ItemValuePeriod / scopeSource
We currently employ 1,111 employees in Singapore, China, Malaysia and United Kingdom. 1,111 employees Group PDF p. 19

Outlook

ItemValuePeriod / scopeSource
OUTLOOK the Group’s expectation is for revenue growth to be positive FY2026, Chairman's statement PDF p. 4
OUTLOOK While the Group remains cautiously optimistic FY2026, Chairman's statement PDF p. 4

Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.

Source: Annual Report 2025 ↗

Corporate information

Registration & contacts

Incorporated In
SINGAPORE
Incorporated On
30 Oct 1998
Email
[email protected]
Telephone
65 62623888
Fax
65 63493877
Registered Office
35 Joo Koon Circle
Singapore 629110
Secretary
Nor Hafiza Alwi
Registrar / Transfer Agent
B.A.C.S. PRIVATE LIMITED
Registrar Address
77 Robinson Road, #06-03 Robinson 77, Singapore 068896
Auditors
DELOITTE & TOUCHE LLP
Other Stock Exchange Listings
*SINGAPORE EXCHANGE LTD.
Country
SINGAPORE
Security Type
stocks